Krsnaa Diagnostics notifies Analyst/Institutional Investor Meeting
Krsnaa Diagnostics will meet with Nuvama AIF virtually on 20 November 2025 for a one-on-one interaction. Discussions will be based on publicly available information.
Investor meet intimations are common and typically have a low impact unless significant details emerge from the meeting.
The announcement is a routine disclosure about an investor meeting, with no indication of positive or negative sentiment.
* Krsnaa Diagnostics Limited will be meeting with Nuvama AIF on 20 November 2025. * The meeting will be a one-on-one interaction conducted virtually, starting from 12:00 Hrs (IST) onwards. * Discussions will be based on publicly available information, and no unpublished price-sensitive information (UPSI) will be discussed. * The schedule is subject to change due to exigencies on the part of the Analyst/Institutional Investor or the Company.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.